Abstract
In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis specific but also found in other inflammatory disorders.
We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL 17/TNFα associated genes specifically expressed in psoriasis, among which IL 36γ was the most outstanding marker. In subsequent immunohistological analyses IL 36γ was confirmed to be expressed in psoriasis lesions only. IL 36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti TNFα treatment. Furthermore, IL 36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases.
These features highlight IL 36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course.
Furthermore, IL 36γ might also provide a future drug target, due to its potential amplifier role in TNFα and IL 17 pathways in psoriatic skin inflammation. 
Introduction
Psoriasis vulgaris (Pso), atopic dermatitis (AD), contact eczema (CE), and lichen planus (LP) all represent common chronic inflammatory skin diseases where differential diagnosis based on clinical features and histology can, in some cases, be difficult. They are associated with variable concomitant illnesses, low health related quality of life, and collectively have a considerable economic burden. Mechanistically, these entities share different genetic and environmental influences and are orchestrated by a complex network of common and specific pro inflammatory mediators that result in the expressed clinical phenotypes.
Despite their at times similar clinical appearance to erythrosquamous plaques, these skin diseases are driven by strictly different pathomechanisms thus offering the possibility for accurate molecular diagnostics. Psoriasis is thought to be mainly mediated by Th1/Th17 cytokines with a central role of TNFα, whereas Th2 cytokines are supposed to play a key role in AD (Bieber et al., 2012; Guttman Yassky et al., 2011; Perera et al., 2012) . CE lesions are characterized by Th1 mediated CCL chemokines, whereas LP is most probably driven by a type I IFN mediated inflammation (Pedersen et al., 2007; Wenzel et al., 2008) .
Since the exact diagnosis of these diseases is a matter of great importance for patient specific therapy, several earlier studies investigated the value of a number of genes and proteins as potential specific biomarkers (Bieber et al., 2012; Villanova et al., 2013) . Unfortunately, most of these markers, like the S100 proteins A7, A8 and A9, are common inflammatory mediators which are highly expressed in psoriasis (Liu et al., 2007; Semprini et al., 1999) but also in other inflammatory skin diseases (Glaser et al., 2009; Kerkhoff et al., 2012) . Here, we present data of 150 patients with different inflammatory skin disorders demonstrating that IL 36γ, an IL 1F cytokine formerly known as IL 1F9, is specifically expressed in psoriasis skin lesions and closely associated with disease activity. 
Results
Chronic skin diseases are characterized by the expression of common pro inflammatory mediators
Initially an unsupervised hierarchical gene cluster analysis to visualize the average linkage of all genes specifically expressed within the different subsets was performed ( Figure 1a ). This identified a set of genes which were commonly upregulated in all inflammatory skin diseases ("general inflammation"), but not in healthy controls.
Importantly, this gene set encompassed nearly all of the top regulated genes found in the different skin diseases as given in Table 1 , including the S100 proteins A7, A8, A9, keratins KRT6 and KRT16, the IFN regulated IFI27 as well as LCE3 and DEFB4.
The mean expression rates of all significantly regulated genes are provided in Supplementary Table 1 .
Downregulation of genes involved in regulation and differentiation of inflammatory skin diseases
Inversely to the pro inflammatory factors commonly expressed in all inflammatory skin diseases, we found a set of jointly downregulated genes, reflecting the diminished immune regulation and differentiation in skin inflammation. These genes included WIF1, which plays a role in tissue differentiation, LTBP4, which is involved in the regulation of TGF beta bioavailability, the keratins KRT8 and KRT18, and the anti inflammatory IL 37, that is a natural suppressor of innate inflammatory and immune responses (Nold et al., 2010) . Expression of specific gene clusters in different inflammatory skin diseases As depicted in Figure 1a , the unsupervised cluster analysis highlighted the expression of specific gene clusters in different skin diseases. Genes associated with CCL chemokines (CCL17, CCL19) and those reflecting a type II IFN driven inflammation (IFITM1, IFI30, SOCS1) were found in AD and LP as well as in CE.
HLA related genes, including HLA DPa1, HLA DRA, and HLA DFB1, were typically found in LP and CE, while type I/III IFN associated genes, including CXCL9, ISG15, Mx1/IFI78, were specifically found in LP, Pso, and CE, but not in AD and HC. These results are in accordance with earlier studies concerning gene markers in these other inflammatory diseases and support the informative value of our approach (Kamsteeg et al., 2010; Pedersen et al., 2007; Wenzel et al., 2008) . IL 17/TNFα associated genes are specifically expressed in psoriasis skin samples In psoriasis, the unsupervised cluster analysis revealed a large set of mainly IL 17/TNFα associated inflammatory genes specifically expressed in this disease (detailed data is provided in supplement 2). Interestingly, this cluster included a number of genes regulated only by a combined effect of TNFα and IL 17, including the inflammatory response genes S100A15 (Koebnerisin), S100A12, the platelet derived growth factor (PLAT), and the cytokines IL 19 and IL 36Ra. Further genes in this cluster were LCN2 (Lipocalin 2), which is regulated by IL 17 alone, and the cytokine IL 36γ, which may be induced by IL 17 or TNFα alone as well as by combined treatment with TNFα and IL 17 (Chiricozzi et al., 2011) . In the next step, we performed a set of Significance Analysis of Microarrays (SAM) (Tusher et al., 2001) comparing the gene expression results in psoriasis with that of the other inflammatory diseases (AD, LP, CE) in order to identify potential markers for psoriasis (s. Figure 1b and Table 2 ). These analyses revealed the upregulation of several specific genes in the psoriasis samples, most of them in concordance with the genes seen in the psoriasis specific cluster achieved by the unsupervised cluster analysis (Figure 1a) , including IL 36γ, IL 36Ra, S100A15, LCN2, ATP12A, GJB6, TGM3, and CD24.
Volcano plot identifies IL 36γ/IL 1F9 as a specific psoriasis marker To focus on single genes that might serve as specific psoriasis biomarkers we used a volcano plot to visualize the most significantly and differentially expressed genes in psoriasis versus the other inflammatory skin diseases (Figure 1c ) (Chen et al., 2007) .
This approach revealed IL 36γ/IL 1F9 as the clear top outlier and therefore we selected this gene as the most promising candidate for our subsequent analysis.
Interestingly, the expression of IL 36γ was only moderately associated with the expression of other potential psoriasis markers, including S100 A7, A8, A9, A15, DEFB4 and IL 19 (ρ = 0.43 0.64, p = 0.018 0.001, see Supplement 2).
Immunohistology confirms the strong expression of IL 36γ in psoriasis To confirm the expression of IL 36γ on the protein level we performed immunohistological analyses in the corresponding skin samples. These analyses clearly reflected the picture of IL 36γ expression observed in the gene expression analyses (Figure 2a) . Psoriasis samples showed a strong expression of IL 36γ in the 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  R  e  v  i  e  w  O  n  l  y   IL 36γ in psoriasis   8 upper epidermal layer, mostly in four and more cell layers, while this staining was only weakly found in the control diseases (AD, LP, CE) and absent in healthy controls ( Figure 2b ). As depicted in Figure 2c , the gene expression score in these samples was closely associated with the histological score (Spearman's ρ = 0.71, p<0.01).
Additionally, we analyzed the lesional IL 36γ expression in pustular psoriasis, which was similar to the psoriasis vulgaris findings (Supplement 3).
Low IL 36γ protein expression in other erythrosquamous skin disorders
In the next step, we included additional erythrosquamous skin diseases with potential differential diagnoses to psoriasis (pityriasis lichenoides/PL, subacute cutaneous lupus erythematosus/SCLE, tinea, and mycosis fungoides/MF, n=5, respectively) in the immunohistological analyses. In all these entities only weak expression of IL 36γ was observed (s. Figure 2b ). IL 36γ serum levels in peripheral blood are enhanced and correlate with disease activity IL 36γ ELISA analyses of peripheral blood serum samples (taken from psoriasis patients in different stages of disease as well as from healthy donors and patients who suffered from atopic dermatitis) were performed to investigate a potential systemic relevance of this cytokine. As depicted in Figure 3a , IL 36γ levels in untreated psoriasis patients were significantly elevated when compared with AD and HC (p<0.01). Importantly, the IL 36γ serum levels in all psoriasis patients (under treatment and untreated) correlated closely to the disease activity as determined by PASI (depicted in Figure 3b To investigate the impact of an anti inflammatory drug on the IL 36γ serum levels, serum samples of 7 psoriasis patients before ("baseline") and after 24 weeks ("under treatment") treatment with the anti TNFα drug etanercept were analyzed. Here, the anti TNF treatment lead to a significant decline of the IL 36γ serum levels (see Figure   3c ). Detailed data is provided in Supplement 4.
Predictive diagnostic value of IL 36γ staining in skin biopsies Finally, we investigated the predictive diagnostic value of immunohistological IL 36γ staining as a diagnostic marker in unclear cases. We identified 21 samples in our database with a clinical follow up of at least two years which had been difficult to classify in the primary histological biopsy (taken between 2009 and 2011) but were diagnosed either "psoriasis" or "eczema" in the meantime. These biopsies were stained for IL 36γ expression, blinded, and evaluated by two experienced dermatopathologists (AD and JW). A strong expression of IL 36γ (≥4 cell layers) was specifically found in psoriasis (n=7), while low expression (≤1 cell layer) was only found in eczema (n=8). 6 cases showed a marginal IL 36γ expression (2 3 cell layers) and could not be certainly classified based on their IL 36γ staining.
Beyond the threshold values (≥4 and ≤1, respectively), the staining was entirely consistent with the clinical diagnosis, i.e., in 15 out of 21 samples we were able to assign a specific diagnosis based solely on IL 36γ staining. 29% of the cases remained unclassified (Figure 3d ). Using the given critical value (≥4) IL 36γ had a highly specific positive predictive diagnostic value for psoriasis. 
Discussion
In the present study gene expression analyses in patients with different inflammatory skin diseases revealed a cluster of genes significantly upregulated in psoriasis which are particularly regulated by IL 17 and TNFα (Chiricozzi et al., 2011) . Among these, IL 36γ was found to be the most specifically regulated gene in psoriasis when compared with other inflammatory skin diseases. This finding was confirmed by immunohistochemistry on the protein level. Importantly, IL 36γ blood serum levels (Blumberg et al., 2007) . These mice developed a psoriasis like skin phenotype characterized by acanthosis, hyperkeratosis, and the presence of a mixed inflammatory cell infiltrate. Additionally, the authors found an These results are confirmed by our own findings, revealing IL 36γ as a highly expressed marker within psoriasis skin lesions. Unlike other markers described earlier in psoriasis, including for example the S100 proteins A7, A8 and A9 (Glaser et al., 2009; Kerkhoff et al., 2012; Liu et al., 2007; Semprini et al., 1999) , IL 36γ was highly specific for psoriatic inflammation but only weakly expressed in other inflammatory skin diseases (AD, CE, LP). This data is in accordance with the results by Kamsteeg et al., who found a high expression of IL 36γ in psoriasis but not in eczematous diseases (Kamsteeg et al., 2010) . In addition to these findings, our IHC results demonstrate the potential impact of this marker in the discrimination of psoriasis against other most common erythrosquamous skin diseases, including also pityriasis lichenoides, subacute cutaneous lupus erythematosus, tinea, and mycosis fungoides.
Recent studies implicate a central role for the IL 36s in the pro inflammatory network in psoriasis. Overexpression of IL 36 in mouse skin leads to a disease quite similar to human plaque psoriasis, and inhibition of IL 36 in human psoriatic skin ameliorates the inflammation (Towne and Sims, 2012) . This psoriasis like dermatitis in mice is driven by IL 36 mediated DC keratinocyte crosstalk (Tortola et al., 2012) . Human keratinocytes derived from patients with psoriasis have been shown to express significantly higher levels of IL 36γ in response to IL 17 than those isolated from et al., 2011) . Furthermore, we demonstrated that IL 36γ might be a helpful diagnostic marker in the at times difficult histological differential diagnosis between eczematous psoriasis and psoriasiform eczema. Here, strong expression of IL 36γ (≥4 cell layers) in immunohistochemistry was found to be a highly specific diagnostic marker for psoriasis.
Conclusion
Our results demonstrate that psoriasis skin lesions are characterized by the expression of a specific gene cluster, including several IL 17/TNFα associated cytokines. Among these, IL 36γ is the most outstanding marker. IL 36γ expression in psoriasis skin lesions is significantly enhanced when compared with other erythrosquamous skin diseases. IL 36γ peripheral blood serum levels are closely Finally, IL 36γ immunohistochemistry has a highly positive predictive value to discriminate psoriasis from eczema skin lesions in unclear cases.
These features highlight IL 36γ as a valuable future biomarker in psoriasis patients, both for diagnostic purposes and for monitoring of disease activity during the clinical course. Furthermore, IL 36γ might also provide a future drug target, due to its potential amplifier role in TNFα and IL 17 pathways in psoriatic skin inflammation. was fixed in 5% formalin solution over night and was subjected to conventional histological investigation and immunohistochemistry. The details of this study have been described before (Wenzel et al., 2008) . Additionally, skin samples of other erythrosquamous skin diseases (Pityriasis lichenoides (PL, n=5), subacute cutaneous lupus erythematosus (SCLE, n=5), Tinea (n=5), mycosis fungoides (MF, n=5), and previously unclassified psoriasiform dermatitis (n=21) were included from the authors archives.
RNA isolation
Isolation of total RNA from skin excision biopsies was performed using TriReagent (Sigma, St Louis, MO) and the NucleoSpin 96 RNAKit (Macherey & Nagel, Dueren, Germany). RNA was quantified by photometrical measurement, and the integrity was assessed using a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). 
Gene expression analyses

Histology and immunohistology
Sections were prepared from formalin fixed, paraffin embedded skin biopsies.
Standard hematoxylin and eosin as well as periodic acid Schiff staining were performed for diagnostic purposes. The protein expression of IL 36γ was analyzed by immunohistochemistry using the monoclonal mouse IgG1 anti human IL 36γ antibody ab156783 (Abcam Inc. ®, Cambridge, MA, USA) without pretreatment with a dilution of 1:500. The lesional IL 36γ expression was scored semiquantitatively (0= no expression; 1= weak expression; 2= fair expression; 3= strong expression) by two experienced dermatopathologists (JW and AD) (Wenzel et al., 2005) . Visualization was performed using the REAL staining kit (DAKO) with Fast Red as chromogen.
IL 36γ blood serum concentrations
Blood samples of patients with psoriasis in stages of untreated active disease ("baseline") as well as after 24 weeks of systemic treatment with etanercept ("24 weeks treatment") (at the dose of 50mg twice a week for 12 weeks followed by 50 mg once a week) were collected in our outpatient clinic (Pso untreated: n=7, Pso treated: 
Statistical analysis
Gene expression analyses
Primary statistical analyses were performed by using the TMEV software (version 4.9). Unsupervised hierarchical cluster analysis with Pearson correlation coefficient was used to investigate the average linkage of the genes within the different subsets (Eisen et al., 1998) . To identify potential marker genes in psoriasis, Significance
Analysis for Microarrays (SAM) was used to identify genes specifically expressed in the different subsets (expression > 2 fold enhanced, p<0.01) (Tusher et al., 2001 ).
This method included two sided unpaired t tests for each of the 1539 unique genes represented on the microarray chip using the R programming environment and the 
Statistics for immunohistochemistry and ELISA analysis
Using SPSS 22, the non parametrical Mann-Whitney U test was performed to compare the mean staining intensity of IL 36γ in the different skin diseases as well as to compare mean serum levels as determined by ELISA. Wilcoxon signed rank test was used to compare IL36γ serum levels before and after Etanercept treatment.
Correlation analyses were performed by calculating Spearman's rho. P level <0.05 was considered to be significant (*) and p level <0.01 as highly significant (**).
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